100 results
Page 2 of 5
8-K
EX-99.1
pjfuy
28 Feb 22
Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies
8:26am
424B5
3pr vkw40r0u
17 Feb 22
Prospectus supplement for primary offering
8:59am
8-K
EX-99.1
k99ddca2c757qflav1t3
10 Jan 22
Regulation FD Disclosure
8:27am
8-K
EX-99.2
tiscql
29 Nov 21
Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics
7:04am
8-K
EX-10.1
sesoae0yctcwmp6xgrsk
28 Jul 21
Other Events
4:15pm
8-K
EX-10.2
itnslsl mn2vcqg
28 Jul 21
Other Events
4:15pm
8-K
EX-99.1
xqr8mjzj
16 Jun 21
FDA Approves Blueprint Medicines’ AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
5:14pm
8-K
EX-99.1
38i4vvj
17 May 21
Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific Officer
8:30am
8-K
EX-99.1
nwy 6ooxrxt0nc8
12 Apr 21
Regulation FD Disclosure
7:40am
8-K
EX-99.1
8tjr87 ubg3
17 Feb 21
Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results
8:00am
8-K
qg9wm7sq8t6k3god
11 Jan 21
Entry into a Material Definitive Agreement
8:20am
8-K
EX-99.2
gc123eb50rzo
11 Jan 21
Entry into a Material Definitive Agreement
8:20am
8-K
EX-99.1
jtrx9muipj1pmg2ggx02
11 Jan 21
Entry into a Material Definitive Agreement
8:20am